Rituxan shows promise as treatment for type-1 diabetes
A new study carried out by researchers at Indiana University School of Medicine in Indianapolis and published in the New England Journal of Medicine suggests that the monoclonal antibody rituximab may benefit people with type 1 diabetes by reducing their need for insulin.
Marketed as Rituxan by Roche and FDA approved in the treatment of non-Hodgkin's lymphoma as well as rheumatoid arthritis, rituximab actually helped patients produce some of their own insulin, although researchers urged caution in interpreting these results and stressed that they did not indicate a cure for the disease.
The phase II study, in which patients received four doses of Rituxan, is part of Roche's attempt to secure FDA approval for the drug as a treatment for type 1 diabetes, a disease which affects as many as two and a half million people in the US, according to the American Diabetes Association.
You can read more about this study at US News & World Report.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
